Promising Breast Cancer Vaccine

Breast cancer vaccine

Could the future of breast cancer medical treatment include a vaccine?  Possibly. According to Moffitt Cancer Center researchers, a dendritic cell vaccine targeting the HER2 protein on breast cancer cells is safe.

The HER2 protein is overexpressed in 20 to 25% of all breast cancer tumours. It is associated with aggressive cancers and a poor prognosis.

How does the vaccine work?

The vaccine is created from dendritic cells (immune cells) harvested from the patient to create a personalised vaccine.  Many therapeutic strategies aim to re-stimulate the immune system to recognise cancer cells and target them for destruction.

It was previously shown that immune cells are less able to recognise and target cancer cells that express HER2, as breast cancer progresses into a more advanced and invasive stage. However, the new vaccine effectively stimulates the immune system leading to regression of early-stage breast cancer.

Putting the vaccine to the test

Researchers performed a clinical trial in 54 women who have HER2-expressing early-stage breast cancer. Patients were injected with a dose of their personal dendritic cell vaccine once a week for six weeks into either a lymph node, the breast tumour, or into both sites.

The dendritic cell vaccines were well-tolerated and patients experienced only low-grade toxicity. The most common adverse events were fatigue, injection site reactions, and chills.

Source: Moffitt Cancer Center via

(0 votes)
| 853 views | January, 5th, 2017
N-Touch News

N-TOUCH News, entertaining and enlightening since 1996

Related items

N-Touch News

N-Touch News is an online venue for our best sponsored content to be featured. A leader in the content marketing space, and our stable of great content creators helps our partners reach and connect to their desired audience. This is where great enlightening content will always be found.

We want to give our buyers and sellers priority access to smarter impressions across the web so they have better targeting, better insights, and better ROI. We do this through impression-level transparency on proprietary audience, content and engagement data segments.

Copyright © 2018 N-Touch News. All Rights Reserved.